STMN1 and neoplasm: In the tumor core, we found that the CLDN18.2-positive group showed significantly higher total CD8+ T cells, CD8+LAG-3− T cells, CD8+PD-1− T cells, and CD8+TIM-3− T cells than the CLDN18.2-negative group did (0.053 vs. 0.037, P = 0.023; 0.039 vs. 0.026, P = 0.009; 0.050 vs.0.035, P = 0.024; 0.045 vs. 0.032, P = 0.038, respectively).